Author Bio Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights What happened Shares of Guardant Health (NASDAQ:GH) were rising 4.7% higher as of 10:54 a.m. EDT on Thursday. The gain came after the company announced that its Guardant Reveal blood test received Clinical Laboratory Evaluation Program (CLEP) approval from the New York State Department of Health in detecting and monitoring residual disease in patients with early-stage cancer. So what The win in New York marked an important milestone for Guardant Health. The company launched its Guardant Reveal product earlier this year. CLEP approval will allow oncologists in the Empire State to use the liquid biopsy test in two ways: identifying high-risk patients with colorectal cancer who could benefit from adjuvant therapy and detecting cancer recurrence.